6/11
08:07 pm
ymab
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate [Yahoo! Finance]
5/29
01:03 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $20.00 to $15.00. They now have an "outperform" rating on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $20.00 to $15.00. They now have an "outperform" rating on the stock.
5/28
12:08 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $21.00.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $21.00.
5/28
12:08 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $21.00.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $21.00.
5/28
06:35 am
ymab
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Medium
Report
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
5/28
04:52 am
ymab
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 [Yahoo! Finance]
Medium
Report
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025 [Yahoo! Finance]
5/27
11:30 am
ymab
Advocacy-led Consensus Sets Path to Better High-Risk Neuroblastoma Care
Neutral
Report
Advocacy-led Consensus Sets Path to Better High-Risk Neuroblastoma Care
5/26
10:07 am
ymab
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting [Yahoo! Finance]
Medium
Report
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting [Yahoo! Finance]
5/26
10:00 am
ymab
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Medium
Report
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
5/19
08:14 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.
5/15
08:07 pm
ymab
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations [Yahoo! Finance]
5/14
12:41 pm
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Truist Financial Co. from $18.00 to $14.00. They now have a "buy" rating on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Truist Financial Co. from $18.00 to $14.00. They now have a "buy" rating on the stock.
5/14
11:13 am
ymab
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $21.00 to $20.00. They now have an "outperform" rating on the stock.
Medium
Report
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $21.00 to $20.00. They now have an "outperform" rating on the stock.
5/13
10:51 pm
ymab
Q1 2025 Y-mAbs Therapeutics Inc Earnings Call [Yahoo! Finance]
High
Report
Q1 2025 Y-mAbs Therapeutics Inc Earnings Call [Yahoo! Finance]
5/13
07:42 am
ymab
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 [Yahoo! Finance]
Low
Report
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 [Yahoo! Finance]
5/13
07:05 am
ymab
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
Low
Report
Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
5/13
06:35 am
ymab
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
Medium
Report
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
5/7
08:13 pm
ymab
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
Medium
Report
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates [Yahoo! Finance]
5/7
07:05 am
ymab
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
Medium
Report
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
5/6
07:05 am
ymab
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Medium
Report
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
4/30
11:52 am
ymab
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline [Yahoo! Finance]
Low
Report
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q1 Earnings Expected to Decline [Yahoo! Finance]
4/28
07:12 am
ymab
HERVolution Appoints Dr. Tine Gaziel as CMO to Advance Dark Genome-Targeting Immune Therapy into the Clinic [Yahoo! Finance]
Medium
Report
HERVolution Appoints Dr. Tine Gaziel as CMO to Advance Dark Genome-Targeting Immune Therapy into the Clinic [Yahoo! Finance]
4/27
03:00 pm
ymab
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
4/27
11:21 am
ymab
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Low
Report
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
4/25
08:19 am
ymab
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma [Yahoo! Finance]
Low
Report
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma [Yahoo! Finance]